A phase I study to evaluate the safety, tolerance and pharmacokinetics of anti‐Shiga toxin hyperimmune equine F (ab′) 2 fragments in healthy volunteers
British Journal of Clinical Pharmacology · 2024
DOI: 10.1111/bcp.15999 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Yanina Hiriart und 12 weiteren Autor:innen. Beteiligte Einrichtung: National Scientific and Technological Research Council, CONICET, Godoy Cruz 2290 (C1425FQB) CABA, Buenos Aires, Argentina. Hauptthemen laut MEDLINE: Shiga Toxin 2, Hemolytic-Uremic Syndrome. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Inmunova SA.
Abstract (Originalsprache)
Aims
Shiga toxin‐producing Escherichia coli ‐haemolytic uraemic syndrome (STEC‐HUS) is considered a toxaemic disorder in which early intervention with neutralizing antibodies may have therapeutic benefits. INM004, composed of F (ab′) 2 fragments from equine immunoglobulins, neutralizes Stx1/Stx2, potentially preventing the onset of HUS.
Methods
A single‐centre, randomized, phase 1, single‐blind, placebo‐controlled clinical trial to evaluate INM004 safety, tolerance and pharmacokinetics (PK) in healthy adult volunteers, was conducted; in stage I, eight subjects were divided in two cohorts ( n = 4) to receive a single INM004 dose of 2 or 4 mg kg −1 , or placebo (INM004:placebo ratio of 3:1). In stage II, six subjects received three INM004 doses of 4 mg kg −1 repeated every 24 h, or placebo (INM004:placebo ratio of 5:1).
Results
Eight subjects (57.1%) experienced mild treatment‐emergent adverse events (TEAEs); most frequent were rhinitis, headache and flushing, resolved within 24 h without changes in treatment or additional intervention. No serious AEs were reported. Peak concentrations of INM004 occurred within 2 h after infusion, with median C max values of 45.1 and 77.7 μg mL −1 for 2 and 4 mg kg −1 , respectively. The serum concentration of INM004 declined in a biphasic manner ( t 1/2 range 30.7–52.9 h). Systemic exposures increased with each subsequent dose in a dose‐proportional manner, exhibiting accumulation. Geometric median C max and AUC values were 149 and 10 300 μg h mL −1 , respectively, in the repeated dose regimen. Additionally, samples from subjects that received INM004 at 2 mg kg −1 showed neutralizing capacity against Stx1 and Stx2 in in vitro assays.
Conclusions
The results obtained in this first‐in‐human study support progression into the phase 2 trial in children with HUS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Scientific and Technological Research Council, CONICET, Godoy Cruz 2290 (C1425FQB) CABA, Buenos Aires, Argentina.
- Inmunova SA, Av. 25 de Mayo 1021 (CP1650), San Martín, Buenos Aires, Argentina.
- Clinical Pharmacology Section, Hospital Italiano de Buenos Aires, Tte. Gral. Juan Domingo Perón 4190, CP (C1181ACH), CABA, Buenos Aires, Argentina.
- Internal Medicine Section, Hospital Italiano de Buenos Aires, Tte. Gral. Juan Domingo Perón 4190, CP (C1181ACH), CABA, Buenos Aires, Argentina.
- Terra Nova Innovation Unit, Hospital Italiano de Buenos Aires, Tte. Gral. Juan Domingo Perón 4190, CP (C1181ACH) CABA, Buenos Aires, Argentina.
- Division of Pediatric Clinical Pharmacology, Department of Pediatrics, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario, Canada.
ORCID-Profile: Yanina Hiriart, Facundo Garcia Bournissen
Förderung
- Inmunova SA
Zitieren
APA
Hiriart, Y., Scibona, P., Ferraris, A., Belloso, W. H., Beruto, V., Garcia Bournissen, F., Zylberman, V., Muñoz, L., Goldbaum, F., Spatz, L., Colonna, M., Sanguineti, S., & Simonovich, V. A. (2024). A phase I study to evaluate the safety, tolerance and pharmacokinetics of anti‐Shiga toxin hyperimmune equine F (ab′) 2 fragments in healthy volunteers. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15999
Vancouver
Hiriart Y, Scibona P, Ferraris A, Belloso WH, Beruto V, Garcia Bournissen F, et al. A phase I study to evaluate the safety, tolerance and pharmacokinetics of anti‐Shiga toxin hyperimmune equine F (ab′) 2 fragments in healthy volunteers. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.15999
BibTeX
@article{Hiriart2024,
author = {Hiriart, Yanina and Scibona, Paula and Ferraris, Augusto and Belloso, Waldo H and Beruto, Valeria and Garcia Bournissen, Facundo and Zylberman, Vanesa and Muñoz, Luciana and Goldbaum, Fernando and Spatz, Linus and Colonna, Mariana and Sanguineti, Santiago and Simonovich, Ventura A},
title = {A phase I study to evaluate the safety, tolerance and pharmacokinetics of anti‐Shiga toxin hyperimmune equine F (ab′) 2 fragments in healthy volunteers},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1111/bcp.15999}
}
EUVIMED